Figure 2. Triple negative breast tumors accumulated less Arg-pyrimidine adducts in comparison with triple positive, HER2− and HER2+ tumors.

(A) Arg-pyrimidine adducts are detectable in breast tissue from reduction mammoplasty. The panels (B) and (C) show a higher magnification (400x) of the cellular regions boxed in panel A. Triple negative lesions (D) exhibited a significantly lower accumulation of Arg-pyrimidine residues compared to triple positive (E), HER2− (F) and HER2+ (G) subtypes, magnification 100x. Immunohistochemical quantification (H) was performed as described in Materials and Methods section.